Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM726HX)

Drug Name
MGCD-0103 Drug Info
Synonyms
Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide
Indication
Disease Entry ICD 11 Status REF
Non-small-cell lung cancer 2C25.Y Phase 2 [1]
Solid tumour/cancer 2A00-2F9Z Phase 2 [2]
Diffuse large B-cell lymphoma 2A81 Phase 1/2 [3]
Melanoma 2C30 Phase 1 [4]
Therapeutic Class
Anticancer Agents
Cross-matching ID
PubChem CID
9865515
ChEBI ID
CHEMBL94525
CAS Number
CAS 726169-73-9
TTD Drug ID
DM726HX
VARIDT Drug ID
DR00735

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Preclinical Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Histone deacetylase (HDAC)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [9]
Sodium phenylbutyrate DMXLBCQ Spinal muscular atrophy 8B61 Approved [10]
HBI-8000 DMDWYUN Non-small-cell lung cancer 2C25.Y Registered [1]
ITF2357 DMFZBNE Duchenne dystrophy 8C70 Phase 3 [11]
Pracinostat DMTD7AB Acute myeloid leukaemia 2A60 Phase 3 [12]
NVP-LAQ824 DM8JWNA Mood disorder 6A60-6E23 Phase 3 [13]
SNDX-275 DMH7W9X Breast cancer 2C60-2C65 Phase 3 [1]
CMS-024-02 DMC4X7L Solid tumour/cancer 2A00-2F9Z Phase 3 [14]
Abexinostat DM91LGU Follicular lymphoma 2A80 Phase 3 [15]
PDX-101 DM6OC53 Plasma cell myeloma 2A83.1 Phase 2 [16]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Histone deacetylase 1 (HDAC1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Vorinostat DMWMPD4 Adult acute monocytic leukemia Approved [5]
Romidepsin DMT5GNL Cutaneous T-cell lymphoma 2B01 Approved [17]
Panobinostat DM58WKG Chronic graft versus host disease Approved [5]
HBI-8000 DMDWYUN Non-small-cell lung cancer 2C25.Y Registered [16]
ITF2357 DMFZBNE Duchenne dystrophy 8C70 Phase 3 [18]
NVP-LAQ824 DM8JWNA Mood disorder 6A60-6E23 Phase 3 [19]
SNDX-275 DMH7W9X Breast cancer 2C60-2C65 Phase 3 [13]
Phenylbutyrate DMBHPDW Urea cycle disorder 5C50.A Phase 2 [20]
Resminostat DMNE1FR Hepatocellular carcinoma 2C12.02 Phase 2 [21]
Sodium butyrate DMKNIVG Acute myeloid leukaemia 2A60 Phase 2 [22]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Putative POTE ankyrin domain family member M (POTEM)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [23]
Testosterone DM7HUNW Hot flushes GA30 Approved [24]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [24]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [25]
Vorinostat DMWMPD4 Adult acute monocytic leukemia Approved [6]
SNDX-275 DMH7W9X Breast cancer 2C60-2C65 Phase 3 [6]
Nabiximols DMHKJ5I Cancer related pain MG30 Phase 3 [26]
(+)-JQ1 DM1CZSJ Testicular cancer 2C80 Phase 1 [27]
Tacedinaline DM1Z74X Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 2 [6]
Scriptaid DM9JZ21 Solid tumour/cancer 2A00-2F9Z Preclinical [6]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By G-protein coupled receptor 183 (GPR183)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [28]
Panobinostat DM58WKG Chronic graft versus host disease Approved [6]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [29]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [6]
Pioglitazone DMKJ485 Amyotrophic lateral sclerosis 8B60.0 Approved [30]
Irinotecan DMP6SC2 Adenocarcinoma 2D40 Approved [31]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [32]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [33]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [34]
Vorinostat DMWMPD4 Adult acute monocytic leukemia Approved [6]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Histone H4 (H4C1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [35]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [36]
Selenium DM25CGV N. A. N. A. Approved [37]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [38]
Methotrexate DM2TEOL Anterior urethra cancer Approved [39]
Quercetin DM3NC4M Obesity 5B81 Approved [40]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [41]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [42]
Panobinostat DM58WKG Chronic graft versus host disease Approved [7]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [43]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Histone H3.1t (H3-4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Quercetin DM3NC4M Obesity 5B81 Approved [44]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [45]
Panobinostat DM58WKG Chronic graft versus host disease Approved [7]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [25]
Decitabine DMQL8XJ Acute myelogenous leukaemia 2A41 Approved [46]
Romidepsin DMT5GNL Cutaneous T-cell lymphoma 2B01 Approved [47]
Arsenic DMTL2Y1 N. A. N. A. Approved [48]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [33]
Vorinostat DMWMPD4 Adult acute monocytic leukemia Approved [49]
Berberine DMC5Q8X N. A. N. A. Phase 4 [50]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Sialidase-1 (NEU1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [38]
Fluoxetine DM3PD2C Bipolar depression Approved [51]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [42]
Panobinostat DM58WKG Chronic graft versus host disease Approved [6]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [52]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [53]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [32]
Gemcitabine DMSE3I7 Anterior urethra cancer Approved [54]
Arsenic DMTL2Y1 N. A. N. A. Approved [55]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [56]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By PH and SEC7 domain-containing protein 3 (PSD3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Quercetin DM3NC4M Obesity 5B81 Approved [40]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [57]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [58]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [59]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [25]
Demecolcine DMCZQGK Solid tumour/cancer 2A00-2F9Z Approved [60]
Diethylstilbestrol DMN3UXQ Gonorrheal vaginitis GA02 Approved [61]
Melphalan DMOLNHF Hematologic disease 3C0Z Approved [62]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [63]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [64]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Ral guanine nucleotide dissociation stimulator-like 1 (RGL1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [65]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [66]
Quercetin DM3NC4M Obesity 5B81 Approved [40]
Panobinostat DM58WKG Chronic graft versus host disease Approved [6]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [58]
Leflunomide DMR8ONJ Arthritis FA20 Approved [67]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [68]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [53]
Demecolcine DMCZQGK Solid tumour/cancer 2A00-2F9Z Approved [60]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [69]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Programmed cell death 1 ligand 1 (CD274)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [70]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [42]
Panobinostat DM58WKG Chronic graft versus host disease Approved [8]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [38]
Thalidomide DM70BU5 Adult T-cell leukemia/lymphoma Approved [71]
Testosterone DM7HUNW Hot flushes GA30 Approved [24]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [72]
Leflunomide DMR8ONJ Arthritis FA20 Approved [67]
Sevoflurane DMC9O43 Anaesthesia 9A78.6 Approved [73]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [25]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By ERBB receptor feedback inhibitor 1 (ERRFI1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [35]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [41]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [74]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [75]
Testosterone DM7HUNW Hot flushes GA30 Approved [24]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [24]
Leflunomide DMR8ONJ Arthritis FA20 Approved [67]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [52]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [25]
2-deoxyglucose DMIAHVU Solid tumour/cancer 2A00-2F9Z Approved [6]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Two pore channel protein 1 (TPCN1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [28]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [42]
Clodronate DM9Y6X7 Hypercalcaemia 5B91.0 Approved [76]
Cidofovir DMA13GD Cytomegalovirus infection 1D82 Approved [76]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [76]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [76]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [76]
Arsenic DMTL2Y1 N. A. N. A. Approved [55]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [77]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [78]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Transmembrane and coiled-coil domain protein 3 (TMCC3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Testosterone DM7HUNW Hot flushes GA30 Approved [24]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [24]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [79]
Enzalutamide DMGL19D Prostate cancer 2C82.0 Approved [80]
2-deoxyglucose DMIAHVU Solid tumour/cancer 2A00-2F9Z Approved [6]
Bleomycin DMNER5S Cervical cancer 2C77.0 Approved [6]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [81]
Vorinostat DMWMPD4 Adult acute monocytic leukemia Approved [82]
Dihydrotestosterone DM3S8XC Prostate hyperplasia GA90 Phase 4 [80]
SNDX-275 DMH7W9X Breast cancer 2C60-2C65 Phase 3 [82]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histone deacetylase (HDAC) TTBH0VX NOUNIPROTAC Inhibitor [1]
Histone deacetylase 1 (HDAC1) TT6R7JZ HDAC1_HUMAN Inhibitor [5]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Ceramide glucosyltransferase OTRT5P5I CEGT_HUMAN Gene/Protein Processing [6]
ERBB receptor feedback inhibitor 1 (ERRFI1) OT7VZ2IZ ERRFI_HUMAN Gene/Protein Processing [6]
G-protein coupled receptor 183 (GPR183) OTRILX7G GP183_HUMAN Gene/Protein Processing [6]
Histone H3.1t (H3-4) OTY6ITYF H31T_HUMAN Post-Translational Modifications [7]
Histone H4 (H4C1) OTB71W46 H4_HUMAN Post-Translational Modifications [7]
PH and SEC7 domain-containing protein 3 (PSD3) OTTN9B9O PSD3_HUMAN Gene/Protein Processing [6]
Programmed cell death 1 ligand 1 (CD274) OTJ0VFDL PD1L1_HUMAN Gene/Protein Processing [8]
Putative POTE ankyrin domain family member M (POTEM) OT7L2HGH POTEM_HUMAN Gene/Protein Processing [6]
Ral guanine nucleotide dissociation stimulator-like 1 (RGL1) OTY6ZHVA RGL1_HUMAN Gene/Protein Processing [6]
Sialidase-1 (NEU1) OTH9BY8Y NEUR1_HUMAN Gene/Protein Processing [6]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7008).
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32.
6 Development and validation of the TGx-HDACi transcriptomic biomarker to detect histone deacetylase inhibitors in human TK6 cells. Arch Toxicol. 2021 May;95(5):1631-1645. doi: 10.1007/s00204-021-03014-2. Epub 2021 Mar 26.
7 A systematic assessment of radiation dose enhancement by 5-Aza-2'-deoxycytidine and histone deacetylase inhibitors in head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):904-12. doi: 10.1016/j.ijrobp.2008.10.032.
8 Essential role of HDAC6 in the regulation of PD-L1 in?melanoma. Mol Oncol. 2016 May;10(5):735-750. doi: 10.1016/j.molonc.2015.12.012. Epub 2016 Jan 6.
9 Transcription-independent heritability of induced histone modifications in the mouse preimplantation embryo. PLoS One. 2009 Jun 30;4(6):e6086.
10 Histone Deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases. Curr Drug Targets. 2010 Nov;11(11):1430-8.
11 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
12 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8365).
13 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
14 US patent application no. 2012,0302,505, Cyclodextrin-based polymers for therapeutic delivery.
15 Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. Invest New Drugs. 2015 Apr;33(2):423-31.
16 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
17 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
18 Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9.
19 NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 1;102(7):2615-22.
20 Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
21 2011 Pipeline of 4SC AG.
22 Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006 Sep;5(9):769-84.
23 Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
24 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
25 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
26 Clinical response to Nabiximols correlates with the downregulation of immune pathways in multiple sclerosis. Eur J Neurol. 2018 Jul;25(7):934-e70. doi: 10.1111/ene.13623. Epub 2018 Apr 16.
27 Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget. 2014 May 15;5(9):2355-71.
28 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
29 Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
30 Peroxisome proliferator activated receptor gamma (PPAR-gama) ligand pioglitazone regulated gene networks in term human primary trophoblast cells. Reprod Toxicol. 2018 Oct;81:99-107.
31 In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells. Mol Cancer Ther. 2005 Jun;4(6):885-900.
32 Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
33 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
34 Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
35 Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
36 Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
37 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
38 Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
39 Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
40 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
41 Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
42 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
43 Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicol Appl Pharmacol. 2012 Jun 1;261(2):204-16.
44 Quercetin augments TRAIL-induced apoptotic death: involvement of the ERK signal transduction pathway. Biochem Pharmacol. 2008 May 15;75(10):1946-58. doi: 10.1016/j.bcp.2008.02.016. Epub 2008 Mar 10.
45 Down-regulation of the tumor suppressor gene retinoic acid receptor beta2 through the phosphoinositide 3-kinase/Akt signaling pathway. Mol Endocrinol. 2006 Sep;20(9):2109-21. doi: 10.1210/me.2005-0321. Epub 2006 Apr 13.
46 Epigenetic silencing of maspin expression occurs early in the conversion of keratocytes to fibroblasts. Exp Eye Res. 2008 Apr;86(4):586-600. doi: 10.1016/j.exer.2008.01.003. Epub 2008 Jan 12.
47 Enhanced transgene expression in urothelial cancer gene therapy with histone deacetylase inhibitor. J Urol. 2005 Aug;174(2):747-52. doi: 10.1097/01.ju.0000164723.20555.e6.
48 Inhalable metal-rich air particles and histone H3K4 dimethylation and H3K9 acetylation in a cross-sectional study of steel workers. Environ Health Perspect. 2011 Jul;119(7):964-9. doi: 10.1289/ehp.1002955. Epub 2011 Mar 8.
49 Combined effects of retinoic acid and histone deacetylase inhibitors on human neuroblastoma SH-SY5Y cells. Mol Cancer Ther. 2007 Apr;6(4):1425-32. doi: 10.1158/1535-7163.MCT-06-0623.
50 Berberine acts as a putative epigenetic modulator by affecting the histone code. Toxicol In Vitro. 2016 Oct;36:10-17. doi: 10.1016/j.tiv.2016.06.004. Epub 2016 Jun 13.
51 Screening autism-associated environmental factors in differentiating human neural progenitors with fractional factorial design-based transcriptomics. Sci Rep. 2023 Jun 29;13(1):10519. doi: 10.1038/s41598-023-37488-0.
52 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
53 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
54 Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance. Breast Cancer Res Treat. 2007 Apr;102(2):157-72.
55 Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
56 Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
57 Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
58 Global effects of inorganic arsenic on gene expression profile in human macrophages. Mol Immunol. 2009 Feb;46(4):649-56.
59 Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
60 Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
61 Identification of biomarkers and outcomes of endocrine disruption in human ovarian cortex using In Vitro Models. Toxicology. 2023 Feb;485:153425. doi: 10.1016/j.tox.2023.153425. Epub 2023 Jan 5.
62 Bone marrow osteoblast damage by chemotherapeutic agents. PLoS One. 2012;7(2):e30758. doi: 10.1371/journal.pone.0030758. Epub 2012 Feb 17.
63 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
64 The thioxotriazole copper(II) complex A0 induces endoplasmic reticulum stress and paraptotic death in human cancer cells. J Biol Chem. 2009 Sep 4;284(36):24306-19.
65 DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
66 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
67 Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
68 Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
69 Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
70 Oxidative stress modulates expression of immune checkpoint genes via activation of AhR signaling. Toxicol Appl Pharmacol. 2022 Dec 15;457:116314. doi: 10.1016/j.taap.2022.116314. Epub 2022 Nov 9.
71 Thalidomide suppresses angiogenesis and immune evasion via lncRNA FGD5-AS1/miR-454-3p/ZEB1 axis-mediated VEGFA expression and PD-1/PD-L1 checkpoint in NSCLC. Chem Biol Interact. 2021 Nov 1;349:109652. doi: 10.1016/j.cbi.2021.109652. Epub 2021 Sep 11.
72 Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
73 CircRNA VIM silence synergizes with sevoflurane to inhibit immune escape and multiple oncogenic activities of esophageal cancer by simultaneously regulating miR-124/PD-L1 axis. Cell Biol Toxicol. 2022 Oct;38(5):825-845. doi: 10.1007/s10565-021-09613-0. Epub 2021 May 20.
74 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
75 Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
76 Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
77 Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
78 Genistein and bisphenol A exposure cause estrogen receptor 1 to bind thousands of sites in a cell type-specific manner. Genome Res. 2012 Nov;22(11):2153-62.
79 The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):124-34.
80 LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188.
81 Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
82 Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.